Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2023 19:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on January 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Provides Corporate Update and 2023 Outlook
January 09, 2023 07:00 ET
|
Travere Therapeutics, Inc.
Company well-positioned for potential FDA Subpart H approval and commercial launch of sparsentan for IgA nephropathy (IgAN) in 1Q23, followed by potential EMA approval in second half of 2023 ...
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present a corporate overview...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 14, 2022 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on December 10, 2022, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 16, 2022 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on November 10, 2022, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
November 15, 2022 08:00 ET
|
Travere Therapeutics, Inc.
Developed in collaboration with the rare kidney disease community, RKD & Me aims to amplify the experiences of people living with rare kidney disease. SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE)...
Travere Therapeutics to Present at Upcoming Investor Conferences
November 09, 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: Jefferies 2022...
Travere Therapeutics Reports Third Quarter 2022 Financial Results
October 27, 2022 16:01 ET
|
Travere Therapeutics, Inc.
EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023 New PDUFA target action date for...
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
October 26, 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present data from its sparsentan programs,...
Travere Therapeutics to Report Third Quarter 2022 Financial Results
October 20, 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2022 financial results on Thursday, October 27, 2022, after the...